Mednax Inc (MD)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -103,613 | -60,408 | 66,335 | 130,964 | -9,580 |
| Total stockholders’ equity | US$ in thousands | 764,938 | 849,061 | 891,632 | 896,692 | 747,717 |
| ROE | -13.55% | -7.11% | 7.44% | 14.61% | -1.28% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-103,613K ÷ $764,938K
= -13.55%
Based on the provided data, Mednax Inc's return on equity (ROE) has exhibited fluctuations over the past five years:
1. In 2020, the ROE was negative at -1.28%, indicating that the company was not generating favorable returns for its shareholders relative to its equity base.
2. In 2021, there was a significant improvement in ROE to 14.61%, suggesting that the company's profitability and efficiency in utilizing equity to generate profits had increased.
3. The ROE decreased in 2022 to 7.44%, although it remained positive, indicating that the return generated for every dollar of shareholders' equity had decreased compared to the previous year.
4. By 2023, the ROE turned negative again at -7.11%, signaling that Mednax Inc was experiencing challenges in generating profits from its equity investments.
5. The negative trend continued into 2024, with ROE declining further to -13.55%, reflecting a significant decrease in the company's ability to generate profits with the available equity.
Overall, the fluctuating ROE values imply that Mednax Inc's performance in terms of generating returns for shareholders relative to the equity invested has been volatile and warrants a thorough analysis of the factors influencing profitability and efficiency within the company.
Peer comparison
Dec 31, 2024